EVAX (Evaxion Biotech) רווח נקי למניה ב-12 החודשים האחרונים

Evaxion Biotech A/S leverages its Inertia AI platform to develop cancer vaccines, generating payments from pharmaceutical behemoths. The TTM annual earnings per share reflects this process, where the parameter value equals -1.05. Digital optimization of development reduces intellectual property costs; however, the lack of stable commercial sales leaves the company's financial position dependent on external grants and subsidies.

Long-term asset screening requires a priority assessment of a business's ability to generate real income. This metric is calculated as the ratio of total net profit over four quarters to the total number of shares outstanding. For Evaxion Biotech (EVAX), which focuses on high-risk AI vaccines, this indicator reflects the efficiency of innovation monetization. Analyzing the rolling year earnings per share allows for the identification of capital resilience against technological shocks. The trend line determines the probability of a future price correction.